{rfName}
HE

Indexed in

License and use

Icono OpenAccess

Citations

40

Altmetrics

Analysis of institutional authors

Pous, AAuthorNotario, LAuthorHierro, CAuthorLayos, LAuthorBuges, CCorresponding Author

Share

January 11, 2024
Publications
>
Review
Sí

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

Publicated to:International Journal Of Molecular Sciences. 24 (14): 11403- - 2023-07-01 24(14), DOI: 10.3390/ijms241411403

Authors: Pous, A; Notario, L; Hierro, C; Layos, L; Bugés, C

Affiliations

Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain - Author
Inst Catala Oncol ICO Badalona, Dept Med Oncol, Badalona 08916, Spain - Author

Abstract

Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10-20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody-drug conjugates and other novel HER2-targeted agents has led to the development of numerous clinical trials showing promising results. This review presents the molecular mechanisms supporting the use of HER2-targeted drugs in combination with immunotherapy and provides an overview of the therapeutic scenario of HER2-positive disease. We focus on the role of immunotherapy but also summarize emerging therapies and combinations under clinical research that may change the standard treatment in HER-2 positive disease in the future.

Keywords

Antibody conjugateAntibody-drug conjugateAntineoplastic agentAntineoplastic agentsB7-h1 expressionCancer immunotherapyCancer researchChemotherapyClinical researchClinical trialsCombination chemotherapyEpidermal growth factor receptor 2Gastric cancerHer2HumanHumansImmunoconjugatesImmunotherapyJunction adenocarcinomaNonhumanNovel therapiesOncogenomicsOpen-labelPathologyPd-1Pd-1/pd-l1Pd-l1Pd-l1 expressionPlus paclitaxelPrognostic-factorProgrammed death 1 ligand 1Programmed death 1 receptorProtein expressionProtein targetingRandomized phase-iiiReceptor, erbb-2ReviewStomach cancerStomach neoplasmsStomach tumorSynergistic effectTrastuzumabTumor immunity

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal Of Molecular Sciences due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 66/313, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biochemistry & Molecular Biology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.97. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.03 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 7.33 (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-02, the following number of citations:

  • WoS: 13
  • Scopus: 15
  • Europe PMC: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 44.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 43 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Pous Badia, Anna) and Last Author (Buges Sanchez, Cristina).

the author responsible for correspondence tasks has been Buges Sanchez, Cristina.